Hawthorn
Best-in-class: Hawthorn
The premier heart-support botanical — improves cardiac output, blood flow and mild blood-pressure control, with strong traditional and clinical backing.
Hawthorn quick facts
| Suggested dose | 300–900 mg standardized extract daily. |
| How often | Daily |
| Who it's for | Heart function, circulation and mild blood-pressure support. |
| Best-in-class brand | Hawthorn |
The best-evidenced cardiac botanical, with genuine trial data as an adjunct in mild heart failure — which is exactly why it shouldn't be treated as a casual supplement. Anything with real inotropic activity can interact with real cardiac medication, digoxin and blood pressure drugs in particular. If you have a diagnosed heart condition this belongs in a conversation with your cardiologist, not in a self-directed stack. Effects build over six to eight weeks.
How Hawthorn actually works
Hawthorn's oligomeric procyanidins act on the heart in two ways that are unusual for a botanical. They inhibit phosphodiesterase, which raises intracellular cyclic AMP in cardiac muscle and produces a mild positive inotropic effect — the heart contracts somewhat more forcefully — and they extend the refractory period, which is protective rather than arrhythmogenic. Separately they promote endothelial nitric oxide release, dilating coronary vessels and lowering the resistance the heart pumps against.
Where to get Hawthorn
Find Hawthorn on iHerb →The evidence for Hawthorn
Graded by what exists behind each claim.
✅ Clinically validated
- RCTs/meta-analyses support improved symptoms and exercise tolerance in mild heart failure; modest blood-pressure benefit.
- Improves coronary blood flow and cardiac contractility.
📊 Correlative data
- Traditional heart-tonic use aligns with the cardiac-function findings.
🧪 Theoretical / extrapolated benefits
- Predicted to act like a mild positive inotrope with vasodilation — increasing contractility via sodium-potassium ATPase inhibition while lowering afterload, which is mechanistically similar in direction to digoxin at a far smaller magnitude.
- That similarity is the safety argument, not a selling point: the predicted additivity with digoxin and with beta-blockers is exactly why this needs a prescriber's knowledge in anyone on cardiac medication.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Hawthorn actually does
Hawthorn is the one botanical in this catalog with a cardiac-specific pharmacology, and the mechanism is not the one most people assume. The active fraction of Crataegus leaf and flower extract is oligomeric procyanidins together with flavonoids, principally vitexin and hyperoside. The best-characterized action is inhibition of the sodium-potassium ATPase, which raises intracellular sodium, reduces sodium-calcium exchange and leaves more calcium available to the contractile apparatus.
That is the digitalis mechanism, at a fraction of the potency. Cardiac glycosides do the same thing with a narrow therapeutic index; hawthorn procyanidins do it weakly enough that the positive inotropic effect is modest and the arrhythmogenic risk is correspondingly smaller Holubarsch 2018. The same mechanism explains why the interaction section below is about digoxin.
The second action is the one that distinguishes it from digitalis and matters more clinically. Hawthorn prolongs the cardiac action potential and the effective refractory period, which is an antiarrhythmic property rather than a proarrhythmic one, and it is the opposite of what a cardiac glycoside does. A positive inotrope that does not shorten refractoriness is an unusual combination.
The vascular action is endothelial and it is where the procyanidins do the same job they do elsewhere. Crataegus extracts increase endothelial nitric oxide release and inhibit angiotensin-converting enzyme in vitro, which reduces afterload. In a failing ventricle, reduced afterload does more for cardiac output than a weak inotrope does Wang 2013.
And there is a coronary flow effect measured in isolated hearts. Extracts increase coronary perfusion, which is the mechanistic basis for the angina claims and the least well translated of the four. The fruit preparations, which are chemically different from the leaf-and-flower ones, carry a partly separate literature Zhang 2022.
Cell, rodent, human — and where it stops
The chain runs cleanly from isolated heart to exercise tolerance in patients, and stops at the point where somebody measured death instead of a symptom.
In isolated tissue the pharmacology transfers. Positive inotropy, prolonged refractoriness and increased coronary flow have been demonstrated repeatedly, and the extract's cardiac profile is unusual enough to be described in its own terms rather than by analogy Holubarsch 2018.
In people with heart failure the symptom and exercise endpoints moved. Randomized trials of the standardized leaf-and-flower extract reported improvements in maximal workload on bicycle ergometry, in pressure-rate product and in symptom scores in New York Heart Association class II and III heart failure, and prospective comparative cohort work reached the same conclusion in practice conditions Habs 2004 Wang 2013.
Then the outcome trial reported and the surrogate did not hold. The benefit-risk assessment of the standardized extract sets the exercise-tolerance and symptom findings against the large morbidity and mortality trial, whose primary composite endpoint was not met Holubarsch 2018. Exercise capacity improved; the endpoint that decides whether a heart failure treatment is worth having did not.
The obstacle to transfer is the same one that governs every heart failure drug developed since. Agents that improve symptoms and exercise tolerance by increasing contractility have a long history of failing or worsening mortality endpoints, because the failing myocardium is energy-limited and inotropy costs oxygen. That the hawthorn trial was neutral rather than harmful is itself informative Holubarsch 2018.
Outside heart failure the human evidence is thinner and milder. A randomized, double-blind, placebo-controlled crossover study of a hawthorn fruit extract drink in patients with mild hypertension or hyperlipidemia reported effects on those markers Zeng 2024, which is a different preparation and a different population from the heart failure literature.
Hawthorn — which form, and does it matter
Leaf-and-flower and fruit are two different medicines and the trials belong to the first. The standardized extract with the clinical evidence is prepared from Crataegus leaf with flower and is specified on oligomeric procyanidin content, typically 18.75 percent. Berry and fruit preparations have a different flavonoid and procyanidin profile and their own, smaller literature Zeng 2024 Zhang 2022.
The standardization marker differs between products and it changes the dose. European extracts are standardized on oligomeric procyanidins; others on vitexin-rhamnoside as total flavonoids. A product declaring 1.8 percent vitexin and one declaring 18.75 percent procyanidins are not comparable, and the trial doses — typically 160 to 1,800 mg a day of the standardized extract — belong to the procyanidin specification.
The exposure profile is a procyanidin profile, which means it is partly microbial. Small oligomers and flavonoid aglycones are absorbed and reach plasma within 1 to 3 hours at low concentrations, undergoing extensive first-pass glucuronidation and sulfation in the enterocyte and liver followed by biliary and renal clearance. Larger oligomers pass to the colon and are depolymerized by bacteria to phenolic acid metabolites over 6 to 24 hours. There is no cytochrome oxidation step of consequence, which is why the interaction list is pharmacodynamic rather than pharmacokinetic.
The clock on the clinical effect is weeks, not doses. The trials dose for 6 to 24 weeks before measuring, and the exercise tolerance differences appear over that period Habs 2004 Wang 2013. Nothing about this extract rewards taking it before an exertion.
What a label rarely says and should. Which plant part, which standardization marker, and at what percentage. Those three decide whether the product corresponds to the trial material at all Zhang 2022.
What would have to be true, and how you would know it was not
1. Predict exercise tolerance improves and predict it is the endpoint the trials used. In New York Heart Association class II heart failure on standard therapy, predict a measurable improvement in maximal workload and in symptom score over 12 to 24 weeks at the standardized extract dose Habs 2004 Wang 2013.
2. The prediction that cuts against the product. Predict no reduction in cardiac death or hospitalization, because the outcome trial's primary composite was not met Holubarsch 2018. A subsequent adequately powered trial showing a mortality or hospitalization benefit would falsify this page and would change the standing of this extract entirely.
3. Predict blood pressure moves a little in mild hypertension. Predict a small reduction in systolic blood pressure and modest lipid changes over weeks with a fruit extract preparation Zeng 2024, and predict the effect is smaller than a first-line antihypertensive by a wide margin.
4. Predict a digoxin interaction that is pharmacodynamic and invisible on a level. Predict that adding hawthorn to digoxin increases the inotropic and bradycardic effect without necessarily changing the measured digoxin concentration, because both act at the same pump Holubarsch 2018. That is exactly the kind of interaction a therapeutic drug monitoring test cannot see.
5. Predict the preparation explains a null result. Predict that a fruit or berry product does not reproduce the leaf-and-flower exercise tolerance findings, because the chemistry and the standardization differ Zhang 2022 Zeng 2024. A head-to-head would settle it and has not been run.
What nobody has tested yet
Nobody has retested the outcome question in the modern treatment era. The mortality trial was run against a background of therapy that has since changed substantially, and the benefit-risk assessment notes the exercise and symptom benefits alongside that null Holubarsch 2018. Whether the extract adds anything to current quadruple therapy is untested.
The two plant parts have never been compared. Leaf-and-flower extract has the clinical literature and fruit preparations dominate the consumer market Zhang 2022 Zeng 2024. A head-to-head at matched procyanidin content would tell a reader which product to buy.
The antiarrhythmic property has never been tested clinically. Prolonged refractoriness without shortened refractoriness is an unusual and potentially useful profile, and no trial has examined arrhythmia endpoints in people Holubarsch 2018.
And the angina claim is preclinical. Increased coronary flow in isolated hearts has never been taken to a controlled trial in stable angina Wang 2013, which is a well-defined population with well-defined endpoints and would be a straightforward study.
Hawthorn — its own safety story, not its category's
Tolerability is good across a large trial base and the complaints are mild. Dizziness, headache, nausea and palpitations, generally transient and dose-related, with the benefit-risk assessment concluding a favorable tolerability profile at the doses studied Holubarsch 2018.
The digoxin interaction is the one that needs naming first. Both act on the sodium-potassium ATPase, so the effects are additive at the pump and the combination raises the risk of bradycardia and arrhythmia. Because the interaction is pharmacodynamic, a normal digoxin concentration does not exclude it.
The other interactions are all additive and predictable. Beta blockers and calcium channel blockers, for heart rate and contractility; nitrates and antihypertensives, for blood pressure; and a theoretical antiplatelet overlap from the procyanidins.
The largest real-world hazard is substitution. Heart failure and angina are conditions with treatments that reduce mortality, and an extract that improves how somebody feels without changing the outcome can delay or displace them Holubarsch 2018. That is the specific harm this page is written to prevent.
Who should not take this without a cardiologist. Anyone with heart failure or angina, which is to say everyone with a reason to take it; anyone on digoxin; anyone pregnant or breastfeeding, where there are no data; and anyone treating chest pain or breathlessness that has not been evaluated. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.
Sources read for this page
- Holubarsch CJF. Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review. Am J Cardiovasc Drugs 2018 · PMID 29080984
- Wang J. Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evidence-Based Approach. Evid Based Complement Alternat Med 2013 · PMID 24459528
- Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without Hawthorn special extract WS 1442. Forsch Komplementarmed Klass Naturheilkd 2004 · PMID 15353901
- Zeng W. Effects of Hawthorn Fruit Extract Drink in Chinese Patients With Mild Hypertension and/or Hyperlipidaemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Dose Response 2024 · PMID 39583031
- Zhang J. Food Applications and Potential Health Benefits of Hawthorn. Foods 2022 · PMID 36140986
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: How far you can walk or how many flights you can climb before breathlessness or tightness stops you, on the same route, timed. Exercise tolerance and symptom scores in mild heart failure are what the randomized trials measured, so that is what this plant has been held to — not sleep, not mood, and not how strong your pulse feels. Walk it 3 times in the 14 days before you start so the baseline is a range rather than a single number.
- How long before it means anything: 6-12 weeks of continuous dosing. The studied range is 300-900 mg of standardized extract daily. Any inotropic effect here is small and cumulative rather than immediate, so if the same route has not got easier by then, the course has answered you.
- What will fool you: A drug interaction reading as a benefit, which is the genuinely dangerous confusion on this page. Hawthorn is predicted to add to digoxin and to beta-blockers, so a slower pulse or a lower reading in anyone on cardiac medication may be additivity rather than improvement — and that is exactly why a prescriber needs to know it is in the cupboard. Heart failure symptoms also swing with fluid and salt week to week, and medication is usually being adjusted at the same time.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Hawthorn — safety & side effects
- Dizziness, nausea and headache, mostly from the blood-pressure effect.
- Interacts with digoxin — it has positive inotropic activity of its own and can potentiate it. Also additive with beta-blockers, nitrates and calcium channel blockers.
- Heart failure is not a self-treatment condition. Hawthorn has real evidence in it, and that is exactly why it belongs alongside cardiology rather than instead of it.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
Build your foundation with Coach Cam
The full Supplement Vault — 371 products across 14 categories with clinical, correlative & theoretical evidence, plus my Thorne partner links — lives inside Skool alongside 278 peptides.
Join Skool — $10/mo →Bloodwork to run alongside Hawthorn
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | Potassium and kidney function — it potentiates digoxin, whose toxicity turns on both |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | The cardiovascular context |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Background inflammation |
The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
Hawthorn — frequently asked questions
What is Hawthorn?
The premier heart-support botanical — improves cardiac output, blood flow and mild blood-pressure control, with strong traditional and clinical backing.
What is the suggested dose of Hawthorn?
300–900 mg standardized extract daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
What are the researched benefits of Hawthorn?
RCTs/meta-analyses support improved symptoms and exercise tolerance in mild heart failure; modest blood-pressure benefit.
Who is Hawthorn for?
Heart function, circulation and mild blood-pressure support.
Where can I buy Hawthorn?
Coach Cam sources Hawthorn from vetted, top-rated brands on iHerb — use the buy link on this page.
Hawthorn inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Hawthorn is used for
Hawthorn appears under 1 goal in the goal router.
Related Cardiovascular supplements
Where this goes next
Hawthorn is the endothelial arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.